Paradigm Biopharmaceuticals (ASX:PAR) - Interim Chairman & CEO, Paul Rennie
Interim Chairman & CEO, Paul Rennie
Source: Paradigm Biopharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Paradigm Biopharmaceuticals (PAR) receives Australian ethics approval for its trial on patients suffering knee osteoarthritis pain
  • Paradigm has nominated eight sites across five states to conduct the Australian arm of the PARA_OA_002 study, with patient recruitment and screening scheduled to begin during Q4
  • The phase three clinical trial will look to evaluate the treatment effects of pentosan polysulfate sodium against a placebo, analysing a change in each patient’s pain
  • The company says it expects to receive a response from the US FDA for its investigational new drug application before the end of September, ahead of starting the American arm of the study
  • Paradigm Biopharmaceuticals last traded at $2.05 on September 23

Paradigm Biopharmaceuticals (PAR) has received Australian ethics approval for its trial on patients suffering knee osteoarthritis pain.

Paradigm has nominated eight sites across five states to conduct the Australian arm of the PARA_OA_002 study, with patient recruitment and screening scheduled to begin during Q4.

The phase three clinical trial will look to evaluate the treatment effects of pentosan polysulfate sodium against a placebo. The primary endpoint of the study will be a change from baseline at Day 56 in WOMAC pain.

The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a widely used set of standardised questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, analysing pain, stiffness and physical function.  

Secondary outcomes of the study include changes from the baseline at multiple time points, out to day 168 in WOMAC pain and function and quality of life.

The company said it expects to receive a response from the US FDA for its investigational new drug application before the end of September, ahead of starting the US arm of the study.

Paradigm’s Chief Executive Officer Paul Rennie said commencing the phase three study is a significant milestone for the company.

“We expect that, in addition to the eight Australian sites, there will be clinical sites in UK and Europe and, subject to the FDA’s response, in the US,” said Mr Rennie.

“Our preparation to expand into these additional sites is well underway.”

Paradigm Biopharmaceuticals last traded at $2.05 on September 23.

PAR by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.

" Beamtree (ASX:BMT) signs A$10.1m RippleDown contract with Ampath

Beamtree (ASX:BMT) has signed a US$7 million (A$10.1 million) five-year contract with Ampath for its RippleDown…
Beamtree (ASX:BMT) - CEO, Tim Kelsey

" Beamtree (ASX:BMT) accelerates international growth with first NHS contracts

Beamtree (ASX:BMT) secures its first NHS (National Health Service) contracts worth about $540,000 in combined annual…
Beamtree (ASX:BMT) - CEO, Tim Kelsey

" Beamtree (ASX:BMT) sees 91pc boost in revenue

Health data analytics company Beamtree (ASX:BMT) has reported a 91 per cent boost in group revenue…